InstrumentpanelPortföljerBevakningslistaGemenskapUpptäckSkärm
NOT FOR DISTRIBUTION

Ingevity Corporation

NYSE:NGVT Aktierapport

Börsvärde: US$2.3b

  • Översikt över företaget
  • Värdering
  • Framtida tillväxt
  • Tidigare resultat
  • Finansiell hälsa
  • Utdelning
  • Förvaltning
  • Ägarskap
  • Övrig information
  • Aktiegemenskap

Ingevity Utdelningar och återköp

Utdelning kriterier kontrolleras 0/6

Ingevity har inte registrerat sig för att betala utdelning.

Viktig information

n/a

Avkastning på utdelning

6.1%

Återköpsavkastning

Total avkastning till aktieägarna6.1%
Framtida utdelningsavkastningn/a
Utdelningstillväxtn/a
Nästa utbetalningsdag för utdelningn/a
Ex utdelningsdagn/a
Utdelning per aktien/a
Utdelningsandeln/a

Senaste utdelnings- och återköpsuppdateringar

Inga uppdateringar

Recent updates

Seeking Alpha • Aug 28

Ingevity: Portfolio Simplification Reveals A High-Margin Regulatory Compounder

Summary Ingevity is transforming into a focused, high-margin regulatory compounder, emphasizing Performance Materials and Pavement Technologies after divesting volatile, lower-quality segments. Q2 '26 results highlight margin inflection: adjusted EBITDA rose 14% to $115M, margin expanded to 36.6%, and EPS increased to $1.74, demonstrating strong operating leverage. Hybrid vehicle adoption and infrastructure spending underpin resilient demand for NGVT’s emissions-control and pavement solutions, while PFAS filtration offers incremental EBITDA growth optionality. NGVT trades at a discount on EV/EBITDA versus peers, but improved business quality and robust free cash flow support a bullish outlook despite EV transition and leverage risks. Read the full article on Seeking Alpha
Analysartikel • Aug 07

Ingevity (NYSE:NGVT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Ingevity Corporation's ( NYSE:NGVT ) solid earnings announcement recently didn't do much to the stock price. We did...
User avatar
Uppdatering av berättelse • Jul 04

NGVT: Share Repurchases And 2026 Guidance Will Support Future P/E Rerating

Analysts have modestly raised their price target for Ingevity to $89.0 from $85.5, citing updated assumptions that include a smaller expected revenue decline, a slightly lower discount rate, and a marginally reduced profit margin and future P/E ratio. What’s in the News for Ingevity Ingevity reaffirmed full year 2026 earnings guidance, with expected net sales in a range of $1.05b to $1.15b.
Analysartikel • Jun 18

Ingevity (NGVT) Stock Could Be 14% Undervalued on Its Portfolio Reshaping Narrative

Ingevity (NGVT) stock has been in focus after recent trading performance, prompting investors to reassess how the company’s materials and specialty chemicals portfolio lines up with its current valuation and recent share price moves. See our latest analysis for Ingevity. At a share price of $73.41, Ingevity has seen a 12.90% 1 month share price return and a 22.17% year to date share price return, while its 1 year total shareholder return of 77.40% points to momentum that has been building...
User avatar
Uppdatering av berättelse • Jun 13

NGVT: Portfolio Reshaping And Buybacks Will Support Future P/E Re Rating

Analysts have maintained their $85.50 price target for Ingevity, citing largely stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their current view. What's in the News Ingevity completed the sale of its Ozark Materials Road Markings product line and divested its North Charleston CTO refinery and most of the Industrial Specialties product line, as part of a portfolio reshaping effort.
User avatar
Uppdatering av berättelse • May 29

NGVT: Share Repurchases And Margin Strength Will Support Future P/E Re Rating

Analysts have maintained their $85.50 price target on Ingevity, citing consistent assumptions for revenue growth, profit margins, discount rate, and future P/E as the basis for their view. What's in the News From January 1, 2026 to March 31, 2026, Ingevity repurchased 774,189 shares, representing 2.18% of its stock, for a total of $51.94 million under its ongoing buyback program announced on August 2, 2022 (Key Developments).
User avatar
Uppdatering av berättelse • May 14

NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge

Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).
User avatar
Uppdatering av berättelse • Apr 28

NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact

Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.
User avatar
Uppdatering av berättelse • Apr 11

NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout

Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.
User avatar
Uppdatering av berättelse • Mar 28

NGVT: Higher P/E Will Rely On Future Margin Delivery

Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.
User avatar
Uppdatering av berättelse • Mar 13

NGVT: Higher P/E Outlook Will Depend On Margin Execution

Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.
User avatar
Uppdatering av berättelse • Feb 24

NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook

Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.
User avatar
Uppdatering av berättelse • Feb 09

NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook

Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.
User avatar
Uppdatering av berättelse • Jan 26

NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook

Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.
User avatar
Uppdatering av berättelse • Jan 10

NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook

Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.
User avatar
Uppdatering av berättelse • Dec 25

NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset

Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.
User avatar
Uppdatering av berättelse • Dec 10

NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential

Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.
Analysartikel • Sep 30

Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?

While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...
Analysartikel • Sep 06

Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
User avatar
Uppdatering av berättelse • Sep 05

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.
User avatar
Uppdatering av berättelse • Aug 06

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.
Analysartikel • Jun 27

Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...
Analysartikel • May 28

Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%

Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...
User avatar
Ny berättelse • May 27

Premium Markets Will Secure Long Term Value

Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.
Analysartikel • Apr 05

Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge

Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...
Analysartikel • Feb 20

Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysartikel • Jan 16

Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...
Analysartikel • Nov 07

What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You

Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...
Analysartikel • Oct 13

Is Ingevity (NYSE:NGVT) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysartikel • Sep 08

Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares

When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...
Seeking Alpha • Aug 27

Ingevity: The Risk-Reward Ratio Is Still Unfavorable

Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking Alpha
Analysartikel • Aug 03

Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...
Analysartikel • Jul 13

Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysartikel • Jun 14

Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?

Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...

Stabilitet och tillväxt i betalningar

Hämta utdelningsdata

Stabil utdelning: Otillräcklig data för att avgöra om NGVT s utdelningar per aktie har varit stabila tidigare.

Växande utdelning: Otillräcklig data för att avgöra om NGVT s utdelningsbetalningar har ökat.


Utdelningsavkastning jämfört med marknaden

Ingevity Utdelningsavkastning jämfört med marknaden
Hur är NGVT:s direktavkastning jämfört med marknaden?
SegmentUtdelningsavkastning
Företag (NGVT)n/a
Marknadens lägsta 25% (US)1.4%
Marknad Topp 25% (US)4.1%
Genomsnitt för branschen (Chemicals)1.8%
Prognosanalytiker (NGVT) (upp till 3 år)n/a

Anmärkningsvärd utdelning: Det går inte att utvärdera NGVT s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Hög utdelning: Det går inte att utvärdera NGVT s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.


Vinstutdelning till aktieägarna

Resultattäckning: Otillräcklig data för att beräkna NGVT s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.


Kontantutbetalning till aktieägarna

Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom NGVT inte har rapporterat några utbetalningar.


Upptäck bolag med stark utdelning

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/09/10 13:04
Aktiekurs vid dagens slut2026/09/10 00:00
Intäkter2026/06/30
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
  • SEC Form 10-K
  • SEC Form 10-Q
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
  • Rapporter från analytiker
  • Blue Matrix
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
  • ICE Marknadsdata
  • SEC Form S-1
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
  • SEC Formulär 4
  • SEC Formulär 13D
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
  • SEC Form 10-K
  • SEC Form DEF 14A
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden
  • SEC Formulär 8-K

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Ingevity Corporation bevakas av 7 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Paretosh MisraBerenberg
John McNultyBMO Capital Markets Equity Research
Jonathan TanwantengCJS Securities, Inc.

Ta bättre investeringsbeslut var som helst

Skanna för att ladda ner
Öppna App StoreÖppna Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Visa datakällor
Marknader
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investeringsidéer
  • Undervärderade bolag
  • Starka utdelningar
  • Insiderköp
  • Kärnenergi
  • Autonoma fordon
  • Artificiell intelligens
  • Krypto och blockkedja
  • Cybersäkerhet
  • Fler idéer
Lager Gemenskaperna
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Funktioner och verktyg
  • Portföljspårning
  • Aktieskärm och varningar
  • Berättelser & rättvisa värden
  • Kalkylator för utdelning
Nyheter & Upptäckter
  • Senaste lagernyheter
  • Global Market Insights
  • Foxhole-forumet
  • Investeringsidéer
  • Gemenskapens berättelser
  • Vad är nytt
Simply Wall St
  • Planer och priser
  • Annonsering
  • Om oss
  • Kontakta oss
  • Karriär
  • Hjälpcenter
  • Lär dig investera i aktier
  • Affiliate-program
  • Affärer & företag
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Villkor och anvisningar
  • Integritetspolicy
  • AI-villkor
  • Guide för finansiella tjänster